FINWIRES · TerminalLIVE
FINWIRES

$HRMY

10 stories mentioning HRMYUpdated 4d ago

Every FINWIRES story that references HRMY, newest first.

What are analysts saying about HRMY?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on HRMY?

Insider Trading

Harmony Biosciences Holdings Insider Sold Shares Worth $1,655,416, According to a Recent SEC Filing

Kumar Budur, Chief Medical Officer, on September 16, 2026, sold 38,452 shares in Harmony Biosciences Holdings (HRMY) for $1,655,416. Following the Form 4 filing with the SEC, Budur has control over a total of 13,115 common shares of the company, with 13,115 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1802665/000200976226000006/xslF345X05/form4-09182026_080908.xml

$HRMY
Insider Trading

Harmony Biosciences Holdings Insider Sold Shares Worth $1,453,169, According to a Recent SEC Filing

Kumar Budur, Chief Medical Officer, on September 04, 2026, sold 33,954 shares in Harmony Biosciences Holdings (HRMY) for $1,453,169. Following the Form 4 filing with the SEC, Budur has control over a total of 13,115 common shares of the company, with 13,115 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1802665/000200976226000005/xslF345X05/form4-09092026_090911.xml

$HRMY
Research

Wolfe Initiates Harmony Biosciences at Outperform With $60 Price Target

Harmony Biosciences (HRMY) has an average rating of overweight and mean price target of $47.36, according to analysts polled by FactSet.

$HRMY
Wire

Harmony Biosciences Shares Rise After Q2 Earnings, Product Revenue Increase

Harmony Biosciences (HRMY) shares were up 6.2% in early Tuesday trading after the company posted higher Q2 results.The company reported Q2 earnings of $1.28 per diluted share, up from $0.68 a year earlier.Analysts polled by FactSet expected $0.96.Net product revenue for the quarter ended June 30 was $261.3 million, up from $200.5 million a year earlier.Analysts expected revenue of $250.8 million.Harmony reiterated its 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.As of June 30, the company said it had $962.5 million in cash, cash equivalents and investments.Price: $37.81, Change: $+2.21, Percent Change: +6.19%

$HRMY
Wire

Update: Harmony Biosciences Shares Fall After CFO Glenn Reicin Steps Down

(Updates the latest stock movement in the first paragraph and the headline.)Harmony Biosciences (HRMY) shares were down about 4.4% after the company said Chief Financial Officer Glenn Reicin stepped down to pursue other opportunities.The company reported Thursday preliminary Q2 net product revenue for Wakix of around $261 million, up 30% year over year.Analysts polled by FactSet expect $249.5 million.The company reiterated its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion.Analysts expect $1.01 billion.In addition, the company said Chief Financial Officer Glenn Reicin stepped down to pursue other opportunities, effective immediately.The company said it named Stephen Mollichella, currently the controller, as interim principal financial officer as it conducts its search for a permanent finance chief.Harmony will report its Q2 financial results on Aug. 4.Price: $33.38, Change: $-1.53, Percent Change: -4.37%

$HRMY
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.2%.In corporate news, Entrada Therapeutics (TRDA) shares tumbled 57% after its drug for children with Duchenne muscular dystrophy fell short of analyst expectations in an early-to-mid stage trial, Reuters reported Thursday.Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5.5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.1% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.

$CPRX$HRMY$IOVA$TRDA
Sectors

Sector Update: Health Care Stocks Decline in Afternoon Trading

Health care stocks declined Thursday afternoon with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.6%.In corporate news, Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.2% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.

$CPRX$HRMY$IOVA
Wire

Harmony Biosciences Shares Fall After Q1 Earnings, Revenue Miss Consensus

Harmony Biosciences (HRMY) shares fell over 6% in Thursday trading after the company's Q1 earnings and revenue fell short of analysts' consensus.The company reported Q1 earnings of $0.55 per diluted share, down from $0.78 a year earlier.Analysts polled by FactSet expected $0.69.Net product revenue for the quarter ended March 31 was $215.4 million, up from $184.7 million a year earlier.Analysts expected revenue of $220.8 million.As of March 31, the company said it had $870.5 million in cash, cash equivalents, and investments.The company reiterated its 2026 WAKIX net revenue guidance of $1 billion to $1.04 billion. Analysts expect $1.01 billion.Price: $29.52, Change: $-3.26, Percent Change: -9.95%

$HRMY
Research

Update: Mizuho Securities Keeps Price Target on Harmony Biosciences to $50, Maintains Outperform Rating

(Updated to keep price target unchanged).Harmony Biosciences (HRMY) has an average rating of overweight and mean price target of $43, according to analysts polled by FactSet.Price: $31.09, Change: $-0.07, Percent Change: -0.22%

$HRMY
Wire

Mizuho Securities Cuts Price Target on Harmony Biosciences to $50 From $46, Maintains Outperform Rating

Harmony Biosciences (HRMY) has an average rating of overweight and mean price target of $43, according to analysts polled by FactSet.Price: $31.07, Change: $-0.09, Percent Change: -0.29%

$HRMY

Track with the FINWIRES app suite

FolioX
FolioX
Track HRMY in your portfolio
WheelAI
WheelAI
Analyze HRMY options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HRMY